Body mass index and age are additional prognostic factors in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors
详细信息 查看全文
- 作者：Yan Song ; M.D.a ; Chunxia Du ; M.D.a ; Wen Zhang ; M.D.a ; Yongkun Sun ; M.D.a ; Lin Yang ; M.D.a ; Chengxu Cui ; M.D.a ; Yihebali Chi ; M.D.a ; Jianzhong Shou ; M.D.b ; shoujzh@126.com" class="auth_mail" title="E-mail the corresponding author ; Aiping Zhou ; M.D.a ; zhouap1825@126.com" class="auth_mail" title="E-mail the corresponding author ; Jinwan Wang ; M.D.a ; Yan Sun ; M.D.a
- 关键词：Renal cell carcinoma ; Kidney ; Tyrosine kinase inhibitors ; Prognosis
- 刊名：Urologic Oncology: Seminars and Original Investigations
- 出版年：2016
- 出版时间：June 2016
- 年：2016
- 卷：34
- 期：6
- 页码：258.e15-258.e22
- 全文大小：760 K
文摘
- ●
The MSKCC prognostic model is also applicable to Chinese patients with mRCC.
- ●
We integrated age and BMI into the MSKCC model to set up a 7-factor prognostic model.
- ●
A 7-factor prognostic model might help to identify patients with the best prognosis.